Cargando…
A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement
This study was conducted to evaluate the efficacy and safety of Unicenta in female subjects with menopausal symptoms by analyzing the changes in the Kupperman index (primary endpoint) and hormonal changes (secondary endpoint). It was a randomized, multi-center, double-blind, parallel, non-inferiorit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456340/ https://www.ncbi.nlm.nih.gov/pubmed/37629679 http://dx.doi.org/10.3390/medicina59081382 |
_version_ | 1785096673694842880 |
---|---|
author | Kim, Seongmin Lee, Sanghoon Ahn, Ki-Hoon Park, Hyun-Tae Song, Jae-Yun Hong, Soon-Cheol Kim, Tak |
author_facet | Kim, Seongmin Lee, Sanghoon Ahn, Ki-Hoon Park, Hyun-Tae Song, Jae-Yun Hong, Soon-Cheol Kim, Tak |
author_sort | Kim, Seongmin |
collection | PubMed |
description | This study was conducted to evaluate the efficacy and safety of Unicenta in female subjects with menopausal symptoms by analyzing the changes in the Kupperman index (primary endpoint) and hormonal changes (secondary endpoint). It was a randomized, multi-center, double-blind, parallel, non-inferiority clinical study conducted at two different tertiary medical centers. A Unicenta injection was shown to be non-inferior to Melsmon based on the Kupperman index in both the intent-to-treat and per-protocol populations (p = 0.789 and p = 0.826, respectively). Additionally, there were no statistically significant differences in hormone levels (estradiol, follicular-stimulating hormone) or in the evaluation of facial flushes. There was no statistically significant difference in the incidence rate of adverse events between the two groups (p = 0.505). The study demonstrated that Unicenta is not inferior to Melsmon in terms of the change in the Kupperman index after 12 days of injection. The efficacy and safety of Unicenta were shown, resulting in the improvement of menopausal symptoms. |
format | Online Article Text |
id | pubmed-10456340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104563402023-08-26 A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement Kim, Seongmin Lee, Sanghoon Ahn, Ki-Hoon Park, Hyun-Tae Song, Jae-Yun Hong, Soon-Cheol Kim, Tak Medicina (Kaunas) Article This study was conducted to evaluate the efficacy and safety of Unicenta in female subjects with menopausal symptoms by analyzing the changes in the Kupperman index (primary endpoint) and hormonal changes (secondary endpoint). It was a randomized, multi-center, double-blind, parallel, non-inferiority clinical study conducted at two different tertiary medical centers. A Unicenta injection was shown to be non-inferior to Melsmon based on the Kupperman index in both the intent-to-treat and per-protocol populations (p = 0.789 and p = 0.826, respectively). Additionally, there were no statistically significant differences in hormone levels (estradiol, follicular-stimulating hormone) or in the evaluation of facial flushes. There was no statistically significant difference in the incidence rate of adverse events between the two groups (p = 0.505). The study demonstrated that Unicenta is not inferior to Melsmon in terms of the change in the Kupperman index after 12 days of injection. The efficacy and safety of Unicenta were shown, resulting in the improvement of menopausal symptoms. MDPI 2023-07-28 /pmc/articles/PMC10456340/ /pubmed/37629679 http://dx.doi.org/10.3390/medicina59081382 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Seongmin Lee, Sanghoon Ahn, Ki-Hoon Park, Hyun-Tae Song, Jae-Yun Hong, Soon-Cheol Kim, Tak A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement |
title | A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement |
title_full | A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement |
title_fullStr | A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement |
title_full_unstemmed | A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement |
title_short | A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement |
title_sort | randomized, multicenter, double-blind, parallel, non-inferiority clinical study to compare the efficacy and safety of unicenta and melsmon for menopausal symptom improvement |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456340/ https://www.ncbi.nlm.nih.gov/pubmed/37629679 http://dx.doi.org/10.3390/medicina59081382 |
work_keys_str_mv | AT kimseongmin arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT leesanghoon arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT ahnkihoon arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT parkhyuntae arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT songjaeyun arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT hongsooncheol arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT kimtak arandomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT kimseongmin randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT leesanghoon randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT ahnkihoon randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT parkhyuntae randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT songjaeyun randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT hongsooncheol randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement AT kimtak randomizedmulticenterdoubleblindparallelnoninferiorityclinicalstudytocomparetheefficacyandsafetyofunicentaandmelsmonformenopausalsymptomimprovement |